- Home
- UAL vs ILMN Comparison
UAL vs ILMN Comparison
Compare UAL & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAL
- ILMN
- Stock Information
- Founded
- UAL 1934
- ILMN 1998
- Country
- UAL United States
- ILMN United States
- Employees
- UAL N/A
- ILMN N/A
- Industry
- UAL Air Freight/Delivery Services
- ILMN Medical Specialities
- Sector
- UAL Consumer Discretionary
- ILMN Health Care
- Exchange
- UAL Nasdaq
- ILMN Nasdaq
- Market Cap
- UAL 24.4B
- ILMN 22.9B
- IPO Year
- UAL N/A
- ILMN 2000
- Fundamental
- Price
- UAL $100.28
- ILMN $141.09
- Analyst Decision
- UAL Strong Buy
- ILMN Buy
- Analyst Count
- UAL 16
- ILMN 20
- Target Price
- UAL $93.08
- ILMN $160.68
- AVG Volume (30 Days)
- UAL 5.2M
- ILMN 2.1M
- Earning Date
- UAL 01-21-2025
- ILMN 11-04-2024
- Dividend Yield
- UAL N/A
- ILMN N/A
- EPS Growth
- UAL N/A
- ILMN N/A
- EPS
- UAL 8.30
- ILMN N/A
- Revenue
- UAL $55,994,000,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- UAL $6.53
- ILMN N/A
- Revenue Next Year
- UAL $7.08
- ILMN $4.28
- P/E Ratio
- UAL $12.08
- ILMN N/A
- Revenue Growth
- UAL 6.67
- ILMN N/A
- 52 Week Low
- UAL $37.02
- ILMN $97.36
- 52 Week High
- UAL $105.09
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- UAL 73.30
- ILMN 48.42
- Support Level
- UAL $95.64
- ILMN $138.88
- Resistance Level
- UAL $105.09
- ILMN $144.00
- Average True Range (ATR)
- UAL 3.07
- ILMN 4.58
- MACD
- UAL -0.32
- ILMN -0.05
- Stochastic Oscillator
- UAL 70.83
- ILMN 69.62
About UAL United Airlines Holdings Inc.
United Airlines is a major US network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large US peers.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.